GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Transcenta Holding Ltd (HKSE:06628) » Definitions » Gross Margin %

Transcenta Holding (HKSE:06628) Gross Margin % : 24.13% (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Transcenta Holding Gross Margin %?

Gross Margin % is calculated as gross profit divided by its revenue. Transcenta Holding's Gross Profit for the six months ended in Dec. 2023 was HK$4.69 Mil. Transcenta Holding's Revenue for the six months ended in Dec. 2023 was HK$19.43 Mil. Therefore, Transcenta Holding's Gross Margin % for the quarter that ended in Dec. 2023 was 24.13%.


The historical rank and industry rank for Transcenta Holding's Gross Margin % or its related term are showing as below:

HKSE:06628' s Gross Margin % Range Over the Past 10 Years
Min: 15.66   Med: 19.52   Max: 26.74
Current: 26.74


During the past 5 years, the highest Gross Margin % of Transcenta Holding was 26.74%. The lowest was 15.66%. And the median was 19.52%.

HKSE:06628's Gross Margin % is ranked worse than
80.8% of 750 companies
in the Biotechnology industry
Industry Median: 60.88 vs HKSE:06628: 26.74

Transcenta Holding had a gross margin of 24.13% for the quarter that ended in Dec. 2023 => Competition eroding margins

The 5-Year average Growth Rate of Gross Margin for Transcenta Holding was 0.00% per year.


Transcenta Holding Gross Margin % Historical Data

The historical data trend for Transcenta Holding's Gross Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Transcenta Holding Gross Margin % Chart

Transcenta Holding Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Gross Margin %
15.66 22.48 18.65 19.52 26.74

Transcenta Holding Semi-Annual Data
Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Gross Margin % Get a 7-Day Free Trial Premium Member Only 20.58 14.12 20.99 28.02 24.13

Competitive Comparison of Transcenta Holding's Gross Margin %

For the Biotechnology subindustry, Transcenta Holding's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Transcenta Holding's Gross Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Transcenta Holding's Gross Margin % distribution charts can be found below:

* The bar in red indicates where Transcenta Holding's Gross Margin % falls into.



Transcenta Holding Gross Margin % Calculation

Gross Margin is the percentage of Gross Profit out of sales or Revenue.

Transcenta Holding's Gross Margin for the fiscal year that ended in Dec. 2023 is calculated as

Gross Margin % (A: Dec. 2023 )=Gross Profit (A: Dec. 2023 ) / Revenue (A: Dec. 2023 )
=15.7 / 58.899
=(Revenue - Cost of Goods Sold) / Revenue
=(58.899 - 43.151) / 58.899
=26.74 %

Transcenta Holding's Gross Margin for the quarter that ended in Dec. 2023 is calculated as


Gross Margin % (Q: Dec. 2023 )=Gross Profit (Q: Dec. 2023 ) / Revenue (Q: Dec. 2023 )
=4.7 / 19.431
=(Revenue - Cost of Goods Sold) / Revenue
=(19.431 - 14.743) / 19.431
=24.13 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


Transcenta Holding  (HKSE:06628) Gross Margin % Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Transcenta Holding had a gross margin of 24.13% for the quarter that ended in Dec. 2023 => Competition eroding margins


Be Aware

If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.


Transcenta Holding Gross Margin % Related Terms

Thank you for viewing the detailed overview of Transcenta Holding's Gross Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Transcenta Holding (HKSE:06628) Business Description

Traded in Other Exchanges
N/A
Address
B6-501, 218 Xinghu Street, Biobay, Suzhou, CHN, 215123
Transcenta Holding Ltd is a clinical stage biopharmaceutical company with fully integrated capacities in discovery, research, development and manufacturing. It is developing nine therapeutic antibody molecules for oncology and selected non-oncology indications including bone and kidney disorders. Geographically the company operates in China (the "PRC") and the USA.
Executives
Qian Xueming 2101 Beneficial owner
Shi Xiaohong 2501 Other
Lav Corporate Gp, Ltd. 2201 Interest of corporation controlled by you
Lav Gp Iii, L.p. 2201 Interest of corporation controlled by you
Lav Biosciences Fund Iii, L.p. 2101 Beneficial owner
Shi Yi 2201 Interest of corporation controlled by you
Lav Asset Management (hong Kong) Limited 2102 Investment manager
Fullerton Management Pte Ltd
Temasek Life Sciences Private Limited
Tls Beta Pte. Ltd.
Hsbc Trust Company (delaware), N.a. 2301 Trustee
Success Link International L.p. 2101 Beneficial owner
Temasek Holdings (private) Limited
Lav Vitality Limited 2101 Beneficial owner
Zhong Guo Guo You Qi Ye Jie Gou Tiao Zheng Ji Jin Gu Fen You Xian Gong Si 2501 Other

Transcenta Holding (HKSE:06628) Headlines

No Headlines